Concepedia
Statistics
Publications
18
Citations
1.7K
H-Index
17
Active since
1985
Affiliations
Stanford University(Current)
Stanford Medicine
SRI International
Marilyn J. Lemmon is an author at Stanford University specializing in medicine, oncology, and radiobiology.
Publications per year
1985–2003
SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
Elaine M. Zeman, Jeremy Brown, Marilyn J. Lemmon et al. · International Journal of Radiation Oncology*Biology*Physics · 1986 · 395 citations
Life Sciences, Cell Biology, Toxicology +8
Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents
Leisa Johnson, Annie Shen, Larry Boyle et al. · Cancer Cell · 2002 · 190 citations · Full text
Medicine, Molecular Biology, Oncology +12
Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
Julia Brown, Marilyn J. Lemmon · PubMed · 1990 · 182 citations
Medicine, Cancer Biology, Oncology +16
Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia.
Mary E. Fox, Marilyn J. Lemmon, Margaret L. Mauchline et al. · PubMed · 1996 · 172 citations
Life Sciences, Biotechnology, Microbiology +14
Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
Carla Heise, Marilyn J. Lemmon, David H. Kirn · PubMed · 2000 · 100 citations
Medicine, Oncology, Pharmacology +16
1–5 of 18